DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Special Investigation of Pregabalin for Fibromyalgia (Regulatory Post Marketing Commitment Plan)

Information source: Pfizer
Information obtained from ClinicalTrials.gov on February 07, 2013
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Pain Associated With Fibromyalgia

Intervention: Pregabalin (Drug)

Phase: Phase 4

Status: Not yet recruiting

Sponsored by: Pfizer

Official(s) and/or principal investigator(s):
Pfizer CT.gov Call Center, Study Director, Affiliation: Pfizer

Overall contact:
Pfizer CT.gov Call Center, Phone: 1-800-718-1021


To collect the efficacy and safety information of Pregabalin on Fibromyalgia patients related to their appropriate use in daily practice.

Clinical Details

Official title: Special Investigation of Pregabalin (Lyrica) for Fibromyalgia

Study design: Observational Model: Case-Only, Time Perspective: Prospective

Primary outcome: Number of Participants with Change from Baseline in Clinical Global Impression of Clinical Condition (CGI-C) at Month X

Detailed description: All the patients whom an investigator prescribes the first pregabalin should be registered consecutively until the number of subjects reaches target number in order to extract patients enrolled into the investigation at random.


Minimum age: N/A. Maximum age: N/A. Gender(s): Both.


Inclusion Criteria:

- Clinical diagnosis of Fibromyalgia

- Pregabalin naive patient

Exclusion Criteria:

- Clinical diagnosis of neuropathic pain

Locations and Contacts

Pfizer CT.gov Call Center, Phone: 1-800-718-1021

Additional Information

To obtain contact information for a study center near you, click here.

Starting date: January 2013
Last updated: January 18, 2013

Page last updated: February 07, 2013

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2015